Tango Therapeutics discloses $152.8M cash; provides vopimetostat clinical update

Tango Therapeutics, Inc.

Estimated cash, cash equivalents, and marketable securities of $152.8M as of Sept 30, 2025 (preliminary, unaudited).
Clinical slide presentation on ongoing Phase 1/2 trial of vopimetostat (TNG462) made available on Oct 23, 2025.
Cash estimate subject to completion of financial closing procedures and may change materially; auditor has not reviewed.
No full financial results or specific clinical data included in the disclosure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.